Our findings revealed a PBRM1-KDM5C-IL-6 axis that influenced antitumor immunity, indicating a potential immunotherapeutic strategy in PBRM1-deficient ccRCC. Here, PBRM1 is linked to nonpapillary renal cell carcinoma.